124I-PGN650

124I-PGN650 is a phosphatidylserine (PS)-targeting F(ab’)2 fully human monoclonal antibody fragment (derived from PGN635) joined to the PET imaging radio-isotope iodine-124 (124I) that is currently evaluated in an exploratory trial for cancer imaging. PS is a molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for the imaging of multiple solid tumor types. In preclinical studies, 124I-PGN650 accumulates in tumor vasculature and provides in vivo tumor images. Additionally, chemotherapies and radiation therapy increase the amount of exposed PS on tumor blood vessels.

Exploratory Study

In April 2012, Peregrine Pharmaceuticals launched its experimental phosphatidylserine (PS)-targeting molecular imaging candidate, 124I-PGN650, into clinical development for the imaging of multiple solid tumor types. The primary goal of this trial is to estimate radiation dosimetry in critical and non-critical organs. Secondary objectives of the trial are tumor imaging and safety. Patients are currently being enrolled in the trial. As of November 25, 2014, the estimated date of completion of this trial is April 2015.